Massive Bio Hires Steve McNamara as Chief Operating Officer to Scale Global AI-Enabled Access to Cancer Clinical Trials and Further Maintain Record Growth

Rhea-AI Summary

Massive Bio announced the appointment of Steve McNamara as Chief Operating Officer, effective immediately. McNamara, with extensive experience at Global Industrial Company (GIC) and other firms, is set to drive operational excellence during a phase of rapid growth. In 2021, Massive Bio achieved a 227% revenue increase, a 110% growth in its pipeline, and expanded its site services by 233%. The company aims to operationalize in 19 countries in 2022 and further enhance its AI-enabled clinical trial enrollment services.

Positive

• Appointment of Steve McNamara as COO expected to enhance operational efficiency.
• Revenue growth of 227% in 2021.
• Plans to expand operations into 19 countries in 2022.
• Successful onboarding of 33,000 patients and partnerships with 24 pharma companies.

Negative

• None.

NEW YORK--(BUSINESS WIRE)-- Massive Bio, Inc., the leader in precision medicine and artificial intelligence (AI)-enabled patient-centric clinical trial enrollment for oncology, announced the hiring of Steve McNamara as chief operating officer. McNamara is a veteran strategic business technology leader who brings deep experience delivering data-driven operational excellence using predictive analytics at global scale. He has managed operations, sales, marketing, product, and service delivery for Global Industrial Company (NYSE: GIC), Component Hardware Group, Inc., and iVillage. McNamara holds a bachelor’s degree in Management from Cornell University, as well as certifications in Leadership Education from Harvard Business School and Northwestern University.

“Steve is a high-impact leader and top consultative strategic business partner who has shown tremendous success in optimizing operations, growing revenues, improving processes, and has developed top-performing sales teams, all over the world. In addition, Steve’s knowledge in private equity run companies made the deal for us," said Selin Kurnaz, Co-Founder and CEO. “This skill set is precisely what is needed at a time of massive growth for the company – In 2021, our revenues grew 227%, our pipeline grew 110%, sites that we serve grew 233%, and our headcount grew 73%. But, we are even more aggressive in 2022 and we plan to make this year as a milestone. We built the foundation in 2021 and we expect to further scale and monetize from that foundation in 2022. We are on target to almost double our footprint and operationalize in 19 countries this year alone. Plus, we will do experiments to build Massive Bio v2.0 and those experiments have the potential to build decacorns," added Kurnaz.

“I am beyond excited to join Massive Bio and help accelerate its global expansion, while continuing to foster its culture of innovation and best-in-class technology and professional service-level organization, using my passion for developing and mentoring outstanding talent and networks. Together we will continue building world-class hub operations, customer service, and supply chain teams with specialty in scaled growth stages," said McNamara. “Massive Bio is truly transforming oncology clinical trials, not only providing improved outcomes for cancer patients in need for novel treatments, but is also poised to propel drug development and efficient patient enrollment to pharmaceutical and biotech companies, CROs and clinical research sites," mentioned McNamara.

“Steve is an impressive leader with a track record that demonstrates self-motivation, understanding of the industry’s challenges, and the perseverance and creativity to achieve both personal and corporate goals at a time of global expansion and market speed velocity for Massive Bio,” mentioned Arturo Loaiza-Bonilla, M.D., Co-Founder of Massive Bio. “We have developed the desired network effects and market product fit within our AI platform to revolutionize the cancer clinical trial ecosystem, and efficiently matching patients at extraordinarily large scales, hence the need for a talented strategic, operational leader like Steve to manage those global networks for the next stage of the company," added Loaiza-Bonilla.

“Steve is not only an accomplished leader, but he has global industry-leading experience with unique ability to design and execute sales plans, identify new segment opportunities, as well as create best practices for customer relationship management (CRM) tools,” said Massive Bio’s Co-founder and Chief Technology Officer (CTO) Cagatay Culcuoglu. “He will be an invaluable addition to our leadership team as we continue to execute on our mission to bring digital health solutions and clinical trials to all cancer patients around the world," mentioned Culcuoglu.

Massive Bio has established global, innovative patient acquisition partnerships with over two dozen patient advocacy groups, data-driven patient identification companies, provider networks, NGS vendors, payers, specialty pharmacies, and local CROs. Throughout 2021, it on-boarded 33,000 patients, partnered with 24 pharmaceutical companies, CROs and health systems, hit 1,000 clinical trial sites, launched the world’s first NASA style Oncology Clinical Trial Command Center (OCTCC), and the largest oncology clinical trial enrollment movement (100K Singularity). All of these milestones require a strong operational leader to fulfill Massive Bio’s mission along with the company’s senior management team.

The new catalog of clinical trial matching solutions are available to cancer patients and research organizations globally, through its website and apps across iOS and Android platforms.

Massive Bio is participating in several events at this week’s J.P. Morgan Healthcare Conference, sharing insights, and evaluating opportunities for collaboration in accelerating AI-enabled oncology clinical trial enrollment. For ongoing insights about its mission and initiatives, follow Massive Bio via our Twitter, LinkedIn, and Facebook channels.

About Massive Bio
Massive Bio’s mission is to provide access to clinical trials for every cancer patient regardless of the patient’s location and/or financial stability. Massive Bio is a proprietary patient recruitment and enrollment enablement solution for oncology clinical trials. Massive Bio provides unique tech enabled services and big data platform that addresses all points of friction in clinical trial enrollment. Massive Bio’s secret sauce is to be the only company in the market that simultaneously provides patient identification, pre-screening and concierge enrollment enablement while being laser focused on oncology and drastically innovating in data, technology, and services in a completely broken clinical trial enrollment value chain. While improving cancer patients lives, Massive Bio serves over two dozen pharmaceutical companies, contract research organizations (CROs) and hospital networks. Massive Bio has been awarded an SBIR contract by the National Cancer Institute (NCI) to develop and characterize its Deep Learning Clinical Trial Matching System (DLCTMS), Contract No. 75N91020C00016. While improving cancer patient’s lives, Massive Bio also provides oncology dedicated data driven patient recruitment, site selection and AI-based trial prescreening services to its enterprise customers. Massive Bio was founded in 2015 and is headquartered in in NYC. Massive Bio has a 50 people team and founded by ex-M&A, clinical and technology executives.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005503/en/

Selin Kurnaz, PhD

Co-founder and CEO of Massive Bio

Phone: (844) 627-7246

Email1: 100KSINGULARITY@massivebio.com

Email2: support@massivebio.com

Website: https://massivebio.com/

Source: Massive Bio, Inc.

FAQ

What does Massive Bio do for cancer patients?

Massive Bio provides access to clinical trials for cancer patients through a tech-enabled patient recruitment and enrollment solution.

What was the revenue growth of Massive Bio in 2021?

Massive Bio reported a revenue growth of 227% in 2021.

Who is the new COO of Massive Bio?

The new COO of Massive Bio is Steve McNamara.

What are the plans for Massive Bio in 2022?

Massive Bio plans to operationalize in 19 countries in 2022, building on its strong growth foundation from 2021.

How many patients did Massive Bio onboard in 2021?

Massive Bio onboarded 33,000 patients in 2021.